Fred Grossman
President at COYA THERAPEUTICS, INC.
Net worth: - $ as of 2024-06-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dieter Weinand | M | 63 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 14 years |
Joseph del Moral | M | 45 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | - |
Howard Berman | M | 50 | 4 years | |
David Snyder | M | 63 | 2 years | |
Gregory Mayes | M | 55 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 2 years |
Ann Lee | M | 62 | 3 years | |
Dov Goldstein | M | 56 | 3 years | |
Barry Fishman | M | 67 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 3 years |
Ellen Lubman | F | 48 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 3 years |
Curtis Weber | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 2 years |
Hideki Garren | M | 60 | 3 years | |
Philip Facchina | M | 62 | 3 years | |
William Perhacs | M | - | 17 years | |
Robert Alexander | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 1 years |
Arun Swaminathan | M | - | 1 years | |
Jessica Starman | F | - | - | |
Jonathan See | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | - |
Tim Power | M | - | 18 years | |
Wilbur Ross | M | 85 | 1 years | |
Hannan Fleiman | M | 44 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 5 years |
Anabella Villalobos | M | 65 | 3 years | |
Dagmar Rosa-Bjorkeson | F | 60 | 4 years | |
John M. Centanni | M | - | 2 years | |
Kristen Laguerre | F | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | - |
Nathan Bryson | M | 61 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 2 years |
Edward Smith | M | 53 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 2 years |
Ansbert Gadicke | M | 66 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | - |
Michelle Frazier | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
James Cornelius | M | 81 | 10 years | |
Nobuhiko Tamura | M | 68 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | 5 years |
Peter R. Dolan | M | 68 | 18 years | |
Mark Iwicki | M | 57 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | 5 years |
Togo Dennis West | M | 81 | 10 years | |
Hiroshi Nomura | M | 66 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | 3 years |
Douglas Manion | M | 64 | 11 years | |
Adrian Hepner | M | 62 | 2 years | |
Jayaram Philkana | M | 54 | 4 years | |
Helen Boudreau | F | 58 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | 3 years |
Carl Decicco | M | 62 | 10 years | |
David J. Helfgott | M | - | - | |
Gerald Bruce | M | 68 | 8 years | |
Louis Gerstner | M | - | - | |
Alan J. Lacy | M | 70 | 12 years | |
Michael Grobstein | M | 81 | 13 years | |
Vicki Sato | M | 75 | 15 years | |
Louis J. Freeh | M | 74 | 8 years | |
John Tsai | M | 57 | 11 years | |
Albert Parker | M | 58 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | 1 years |
Robert Williams | M | 75 | 7 years | |
James Robinson | M | 88 | 29 years | |
Lena Elisabeth Svanberg | M | 63 | 7 years | |
Jon Wigginton | M | 62 | 5 years | |
David Wishart | M | - | 10 years | |
John Golubieski | M | 59 | 16 years | |
Qin Xia | F | 56 | 1 years | |
James Daniel Guylain Priour | M | 57 | - | |
Christopher Bowden | M | 63 | 3 years | |
Yadagiri R Pendri | M | 68 | 7 years | |
Michael Williams | M | - | 1 years | |
Ramy Ibrahim | M | 49 | 6 years | |
Thomas Gibbs | M | 52 | 5 years | |
Dimitry Nuyten | M | 48 | 5 years | |
Randall Owen | M | - | 6 years | |
David Berman | M | - | 10 years | |
Jennifer Herron | F | 54 | 10 years | |
Steven G. Sullivan | M | 59 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | 1 years |
Ronald Cooper | M | 61 | 7 years | |
Sheila Gujrathi | M | 53 | 3 years | |
John Houston | M | 64 | 6 years | |
James Patrick McDermott | M | - | 3 years | |
Howard Feldman | M | - | - | |
Charles Laranjeira | M | 58 | 2 years | |
Andrew Bonfield | M | 61 | 5 years | |
Wendy Dixon | M | 68 | 8 years | |
John L. McGoldrick | M | 83 | 10 years | |
James R. Ellinghausen | M | 65 | 8 years | |
William Jones | M | 60 | 12 years | |
Kimberly A. Hendricks | F | 60 | 3 years | |
Andrew Shenker | M | 69 | 5 years | |
Freda Lewis-Hall | M | 69 | 5 years | |
Lynn H. Clark | F | 66 | 8 years | |
Stuart Tross | M | 57 | 8 years | |
Ellen Futter | F | 74 | 6 years | |
Louis Sullivan | M | 90 | - | |
Tamar Howson | F | 75 | 6 years | |
John P. Amos | M | 57 | 2 years | |
Fu-Min Su | M | - | 6 years | |
Lubor Gaal | M | 56 | 9 years | |
Roger Theodoredis | M | 65 | 3 years | |
David Ian Johnson | M | 66 | 12 years | |
Erin E. Lanciani | F | 55 | 5 years | |
Matthew Ros | M | 57 | 17 years | |
Angela Ogden | M | - | 1 years | |
Raymond T. Keane | M | 65 | 20 years | |
Laurie Alsup | M | 70 | 10 years | |
Stephen E. Bear | M | 73 | 7 years | |
Richard Colonno | M | 74 | 16 years | |
Claude Nicaise | M | 71 | 25 years | |
Cheryl Capps | F | 62 | 13 years | |
Quentin Roach | M | 57 | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 84 | 84.00% |
Canada | 14 | 14.00% |
Australia | 2 | 2.00% |
India | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Fred Grossman
- Personal Network